U.S. Biotech Stock News

Reynolds Consumer Products recently reported full-year 2025 results, with revenue of US$3.72 billion and net income of US$301 million, and issued 2026 guidance that points to flat-to-slightly changing sales and higher earnings per share alongside an affirmed quarterly dividend of US$0.23. Management highlighted broad market share gains, margin improvement and ongoing innovation, but paired these achievements with cautious 2026 revenue guidance amid competitive pricing pressure and persistent...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Newell Brands has reduced its sourcing exposure to China, shifting its supply chain footprint. The company is rolling out automation and AI tools to improve productivity across its global operations. Management is resetting pricing after some customers pushed back on previous price levels. Newell Brands recorded a substantial impairment of acquired intangible assets in its latest quarter. Newell Brands (NasdaqGS:NWL) is making these changes while its shares trade at $4.63. The stock is up...

Patrick Industries, Inc. reported past fourth-quarter 2025 results with sales rising to US$924.17 million and net income to US$29.08 million, alongside higher earnings per share versus a year earlier. The company also delivered full-year sales of US$3.95 billion, maintained solid profitability, completed multiple marine-focused acquisitions, and raised its quarterly dividend to US$0.47 per share, underscoring its emphasis on both growth and shareholder returns. Against this backdrop, we’ll...

Why Ralph Lauren’s latest earnings and outlook update matter for investors Ralph Lauren (RL) just delivered quarterly results that topped earlier commitments and lifted its full year revenue and operating margin guidance, while also flagging upcoming margin pressure from higher tariffs and heavier marketing spend. For you as an investor, that mix of raised full year expectations and near term cost headwinds puts the focus on how durable the company’s current momentum really is across regions,...

Q4 earnings miss and revenue softness weigh on RPC (RES) RPC (RES) stock moved after the company reported fourth quarter 2025 results, posting a net loss and sequential revenue decline as industry softness, seasonal factors and accounting changes pressured margins. For the fourth quarter, RPC reported sales of US$425.78 million compared with US$335.36 million in the same period a year earlier, while net loss was US$3.06 million versus net income of US$12.76 million. Basic and diluted loss per...

Why Huntsman is back in focus for investors Huntsman (HUN) is drawing fresh attention as it prepares to release its fourth quarter and full year 2025 financial and operating highlights, while flagging adjusted EBITDA at the low end of guidance after a Rotterdam outage. See our latest analysis for Huntsman. The sharp recent moves in Huntsman’s share price, including a 24.4% 7 day share price return and a 62.36% 90 day share price return to US$13.46, suggest momentum building into the earnings...

If you are wondering whether Medical Properties Trust at around US$5.36 is a potential bargain or a value trap, you are not alone. A closer look at its valuation can help you frame that question more clearly. The stock is up 6.8% over the last 7 days and 5.5% year to date. That sits against a 20.0% return over 1 year and much larger declines of 41.4% over 3 years and 64.1% over 5 years. Recent news around Medical Properties Trust has largely focused on its balance sheet strength, asset...

If you are trying to work out whether Bloom Energy's share price makes sense today, you first need to understand what the current market price is really implying about the business. The stock has had a mixed recent run, with a 5.5% decline over the last 7 days, a 6.7% gain over 30 days, a 44.9% return year to date, and a very large 1 year return that sits between 4x and 5x. These moves sit against a backdrop of ongoing investor attention on fuel cell and clean energy names. Bloom Energy...

Options trading in Chewy (NYSE:CHWY) has spiked ahead of its upcoming earnings announcement. The Put/Call Ratio is unusually high, with put contracts seeing far higher than expected activity. This options activity points to strong bearish sentiment and increased volatility expectations around the earnings release. Chewy, the online pet products and services retailer, sits at the intersection of e commerce and the pet care industry, an area that often attracts investors looking for consumer...

If you are wondering whether Hershey at around US$231.53 is still reasonable value after a strong run, this article walks through the key numbers that matter. The stock has recent returns of 18.9% over 7 days, 22.5% over 30 days, 26.9% year to date and 54.3% over 1 year, which naturally raises questions about how the current price lines up with the fundamentals. Recent news coverage has focused on Hershey as a long established consumer brand, with attention on how staple food companies are...

Recent share performance and business context Dauch (DCH) has recently attracted attention after a period of strong share price movement, with the stock up about 10% over the past month and roughly 40% in the past 3 months. The Detroit based driveline and metal forming supplier, which supports electric, hybrid, and internal combustion vehicles across major global regions, now trades around $8.62 with a value score of 4 and reported annual revenue of $5,833.6 million. See our latest analysis...

Strategy Inc. (NasdaqGS:MSTR) reported a historic quarterly loss, driven primarily by unrealized losses on its large Bitcoin holdings after a sharp cryptocurrency selloff. Despite the loss, the company added more Bitcoin to its treasury and raised fresh capital to support its Bitcoin focused balance sheet. Management also expanded the company’s Digital Credit instrument and addressed investor questions on liquidity, risk controls, and long term balance sheet flexibility. Strategy Inc...

If you are wondering whether Bausch Health Companies at around US$5.88 is a bargain or a value trap, you are not alone. This article is built to help you weigh that up with a clear look at the numbers. The stock has seen mixed recent returns, with a 2.4% gain over the last 7 days, a 20.6% decline over the past month, and returns of 18.4% lower year to date and 8.8% lower over the past year, set against a much steeper 81.2% decline over five years. Recent news coverage around Bausch Health...

In early February 2026, Twist Bioscience reported first-quarter fiscal 2026 revenue of US$103.7 million, up from US$88.71 million a year earlier, while maintaining a quarterly net loss of US$30.51 million and issuing raised revenue guidance for both the second quarter and full fiscal year 2026. An interesting feature of this update is how Twist’s silicon-based DNA synthesis platform and expanding customer base are underpinning its twelfth consecutive quarter of revenue growth and...

Recent news highlighted how U.S. government initiatives such as Project Vault and possible Defense Production Act support are boosting attention on TMC The Metals Company’s deep-sea polymetallic nodule mining plans, alongside new funding including a US$37 million direct investment and a US$85.2 million strategic commitment from Korea Zinc. This combination of policy momentum and fresh capital underscores TMC’s role in efforts to secure alternative battery metal supplies and reduce reliance...

DoubleVerify Holdings (DV) came under pressure after new generative AI models from Anthropic and OpenAI showed they can automate complex software auditing and code management, prompting investors to reassess potential long term demand for some enterprise software offerings. See our latest analysis for DoubleVerify Holdings. Beyond the latest AI concerns, DoubleVerify’s share price has been weak for some time, with a 7 day share price return of 13.68% and a 1 year total shareholder return...

If you are wondering whether Microsoft is fairly priced or if the recent pullback has improved the value on offer, you are not alone. This article is aimed directly at that question. Microsoft's share price last closed at US$401.14, with returns of a 6.8% decline over 7 days, a 16.3% decline over 30 days, a 15.2% decline year to date and a 1.4% decline over 1 year, while the 3 year and 5 year returns sit at 56.1% and 70.6% respectively. These moves are occurring against a backdrop of ongoing...

Wondering if Antero Midstream at around US$19.18 is offering fair value or if the market is missing something? This article walks through the key signals that matter for you. The stock has recent returns of 1.9% over 7 days, 10.8% over 30 days, 6.9% year to date, 25.4% over 1 year, 116.4% over 3 years and 205.3% over 5 years, which gives useful context before you weigh up what you are paying today. Recent attention on Antero Midstream has focused on its role as an energy infrastructure...

Why Innodata’s new Palantir work matters for investors Innodata (INOD) has been tapped to supply training data and data engineering services to Palantir Technologies, supporting AI platforms that analyze complex rodeo video and sensor data for performance metrics. This new client engagement sits alongside Innodata’s existing data engineering segments and arrives as the company prepares to report fourth quarter and full year 2025 results on February 26, 2026, with a post market release and...

This article explores what Micron Technology’s current price may be implying for investors who are considering whether the stock still offers value after a strong run, or whether the easiest opportunities may have already passed. The stock recently closed at US$394.69, with a 7 day return of a 4.9% decline, a 30 day return of 14.4%, a year to date return of 25.1% and a 1 year return of 329.0%. Recent moves have therefore been very large over multiple time frames. Recent attention on Micron...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) is back in focus after practice changing HERIZON GEA trial results and plans to file a supplemental Biologics License Application in 2026 for first line gastroesophageal adenocarcinoma therapies. See our latest analysis for Jazz Pharmaceuticals. Investors have responded positively to the HERIZON GEA update, with a 24.26% 90 day share price return from Jazz Pharmaceuticals and a 37.58% 1 year total shareholder return, suggesting momentum has picked up...

Why Relay Therapeutics (RLAY) is on investors’ radar Relay Therapeutics (RLAY) has drawn attention after a strong stretch of share price performance, including a positive move over the past month and an even stronger gain in the past 3 months. See our latest analysis for Relay Therapeutics. At a latest share price of $8.92, Relay Therapeutics has seen momentum build, with a 1 day share price return of 9.45% and a 90 day share price return of 44.57%, while the 1 year total shareholder return...

Ermenegildo Zegna (ZGN) is back in focus after reporting unaudited fourth quarter and full year 2025 revenues and receiving an upgrade from UBS, which has drawn fresh attention to the company’s recent operating trends. See our latest analysis for Ermenegildo Zegna. The latest unaudited revenue update and the UBS upgrade have come alongside a sharp rebound in sentiment, with a 7 day share price return of 19.56% and a 1 year total shareholder return of 20.47%. This suggests momentum has...